Market Overview

As Price Falls, Vetr Upgrades GlaxoSmithKline To Buy

Share:
Related GSK
VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO
Dynavax Awaits FDA Verdict On Hepatitis B Vaccine
Tracking Tweedy Browne Portfolio - Q3 2017 Update (Seeking Alpha)

The Vetr crowd on Thursday upgraded its rating for GlaxoSmithKline plc (ADR) (NYSE: GSK) from 3 stars (Hold), issued 527 days ago, to 4 stars (Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.

Share price in GSK took a pronounced downturn throughout April, in part due to the company's recall of 600,000 defective inhalers that occasionally failed in delivering the correct amount of medication per use.

GSK's stock has fallen more than 2.5 percent since the beginning of the month and was recently trading around $40.80.

Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for GlaxoSmithKline is up at $45.30, which is still just below the average analyst target price of $45.67. Less than 2 percent of Vetr users are holding GSK in their watch lists.

Latest Ratings for GSK

DateFirmActionFromTo
Oct 2017Bank of AmericaDowngradesBuyNeutral
Jul 2017CitigroupDowngradesBuyNeutral
Sep 2016PiperJaffrayInitiates Coverage onOverweight

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Health Care Price Target Crowdsourcing Analyst Ratings General

 

Related Articles (GSK)

View Comments and Join the Discussion!

Partner Center